Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

PHARMACEUTICALS

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

DAPAGLIFLOZIN IMPURITY A CRS (10 MG)

DAPAGLIFLOZIN IMPURITY A CRS (10 MG)

ND

DISCOVER
DAPAGLIFLOZIN PROPYLENE GLYCOL MONOHYDRATE CRS (120 MG)

DAPAGLIFLOZIN PROPYLENE GLYCOL MONOHYDRATE CRS (120 MG)

ND

DISCOVER
SORAFENIB FOR PEAK IDENTIFICATION A CRS (10 MG)

SORAFENIB FOR PEAK IDENTIFICATION A CRS (10 MG)

ND

DISCOVER
MEMANTINE HYDROCHLORIDE CRS (10 MG)

MEMANTINE HYDROCHLORIDE CRS (10 MG)

ND

DISCOVER
DAPAGLIFLOZIN IMPURITY B CRS (10 MG)

DAPAGLIFLOZIN IMPURITY B CRS (10 MG)

ND

DISCOVER
CHLORHEXIDINE FOR SYSTEM SUITABILITY A CRS (10 MG)

CHLORHEXIDINE FOR SYSTEM SUITABILITY A CRS (10 MG)

ND

DISCOVER
ROSUVASTATIN ZINC TETRAHYDRATE CRS (90 MG)

ROSUVASTATIN ZINC TETRAHYDRATE CRS (90 MG)

ND

DISCOVER
MEMANTINE IMPURITY B CRS (0.036 MG)

MEMANTINE IMPURITY B CRS (0.036 MG)

ND

DISCOVER
FLUMETASONE PIVALATE FOR ID AND ASSAY CRS (110 MG)

FLUMETASONE PIVALATE FOR ID AND ASSAY CRS (110 MG)

ND

DISCOVER
OLODATEROL HYDROCHLORIDE CRS (60 MG)

OLODATEROL HYDROCHLORIDE CRS (60 MG)

ND

DISCOVER
OLODATEROL FOR SYSTEM SUITABILITY CRS (0.02 MG)

OLODATEROL FOR SYSTEM SUITABILITY CRS (0.02 MG)

ND

DISCOVER
OLODATEROL IMPURITY C CRS (0.002 MG)

OLODATEROL IMPURITY C CRS (0.002 MG)

ND

DISCOVER